Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

5(83.3%)

N/A

1(16.7%)

6Total

Phase 4(5)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07332689Completed

Safety Study of Quadrivalent Subunit Influenza Vaccine in People Aged 3 Years and Older

Role: collaborator

NCT03727230Not ApplicableCompleted

RhD+ Blood Transfusion to Asian-type DEL Recipients

Role: collaborator

NCT02764671Phase 4Unknown

Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Neonates

Role: collaborator

NCT02173899Phase 4Completed

Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine

Role: collaborator

NCT01982409Phase 4Unknown

Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children

Role: collaborator

NCT01815073Phase 4Completed

Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine

Role: collaborator

NCT01817270Phase 4Completed

Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine

Role: collaborator

All 7 trials loaded